Biliary Tract Cancer

Common Name(s)

Biliary Tract Cancer

Bile Tract Cancer is a rare digestive cancer characterized by abnormal cell growth in the bile ducts and gallbladder. Individuals with this disorder may grow harmful tumors that can spread to the rest of the body if not diagnosed early. The bile duct system is responsible for storing and transporting bile from the liver, where it is made, to the intestines, where it helps to digest food. Incomplete development of the ducts inhibits the flow of bile. Individuals with this defect have digestion problems as well as a yellow discoloration of the eye and skin (jaundice). Doctors are usually able to diagnose this defect early in the abnormal growth process, as the resulting symptoms are quickly apparent. Treatment is developed on a case-by-case basis and depends on the specific needs of the patient. For prevention measures, digestion specialists may suggest individuals eat a lower-fat diet, or undergo surgery to relieve the blockage or create a tube to allow bile to reach the digestive system. If an individual's cancer has progressed, doctors may suggest chemotherapy to combat cancer symptoms.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Biliary Tract Cancer" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Biliary Tract Cancer" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Biliary Tract Cancer" returned 140 free, full-text research articles on human participants. First 3 results:

A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer.
 

Author(s): Takuya Sakamoto, Shogo Kobayashi, Daisaku Yamada, Hiroaki Nagano, Akira Tomokuni, Yoshito Tomimaru, Takehiro Noda, Kunihito Gotoh, Tadafumi Asaoka, Hiroshi Wada, Koichi Kawamoto, Shigeru Marubashi, Hidetoshi Eguchi, Yuichiro Doki, Masaki Mori

Journal:

 

Epithelial-mesenchymal transition (EMT) is involved in the characteristics of malignancy, such as invasion, metastasis, and chemoresistance. In biliary tract cancer (BTC), EMT is induced by transforming growth factor-beta 1 (TGF-β1). The EMT is reversible; therefore, it is conceivable ...

Last Updated: 5 Jan 2016

Go To URL
Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101).
 

Author(s): Yutaka Fujiwara, Shogo Kobayashi, Hiroaki Nagano, Masashi Kanai, Etsuo Hatano, Masanori Toyoda, Tetsuo Ajiki, Yuki Takashima, Kenichi Yoshimura, Akinobu Hamada, Hironobu Minami, Tatsuya Ioka

Journal:

 

Biliary tract cancer (BTC) patients who have undergone surgical resection with major hepatectomy cannot tolerate the standard gemcitabine regimen (1,000 mg/m2 on days 1, 8, and 15 every 4 weeks) due to severe toxicities such as myelosuppression. Our dose-finding study of adjuvant ...

Last Updated: 4 Dec 2015

Go To URL
Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction.
 

Author(s): Takashi Shibata, Tomoki Ebata, Ken-ichi Fujita, Tomoya Shimokata, Osamu Maeda, Ayako Mitsuma, Yasutsuna Sasaki, Masato Nagino, Yuichi Ando

Journal: Cancer Sci.. 2016 Feb;107(2):168-72.

 

A clear consensus does not exist about whether the initial dose of gemcitabine, an essential anticancer antimetabolite, should be reduced in patients with liver dysfunction. Adult patients with biliary tract or pancreatic cancer were divided into three groups according to whether ...

Last Updated: 27 Feb 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Biliary Tract Cancer" returned 9 free, full-text review articles on human participants. First 3 results:

Optimum chemotherapy for the management of advanced biliary tract cancer.
 

Author(s): Marwan Ghosn, Hampig Raphael Kourie, Elie El Rassy, Ralph Chebib, Fadi El Karak, Colette Hanna, Dolly Nasr

Journal: World J. Gastroenterol.. 2015 Apr;21(14):4121-5.

 

Biliary tract cancers (BTCs) are highly fatal malignancies, which are often diagnosed at an advanced stage and have relatively poor prognosis. The treatment of patients with advanced BTC is systemic, based on chemotherapy or best supportive care, depending on their performance status. ...

Last Updated: 20 Apr 2015

Go To URL
Efficacy and safety of gemcitabine-based chemotherapies in biliary tract cancer: a meta-analysis.
 

Author(s): Heng Liu, Qi-Di Zhang, Zheng-Hong Li, Qing-Qing Zhang, Lun-Gen Lu

Journal: World J. Gastroenterol.. 2014 Dec;20(47):18001-12.

 

To investigate the efficacy and safety of gemcitabine (Gem)-based combination chemotherapies for the treatment of advanced biliary tract cancer.

Last Updated: 30 Dec 2014

Go To URL
Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review.
 

Author(s): Frédéric Fiteni, Thierry Nguyen, Dewi Vernerey, Marie-Justine Paillard, Stefano Kim, Martin Demarchi, Francine Fein, Christophe Borg, Franck Bonnetain, Xavier Pivot

Journal: Cancer Med. 2014 Dec;3(6):1502-11.

 

Cisplatin/gemcitabine association has been a standard of care for first-line regimen in advanced biliary tract cancer nevertheless oxaliplatin/gemcitabine regimen is frequently preferred. Because comparative effectiveness in clinical outcomes of cisplatin- versus oxaliplatin-containing ...

Last Updated: 5 Jan 2015

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
 

Status: Not yet recruiting

Condition Summary: Biliary Tract Cancer; Biliary Tract Neoplasms

 

Last Updated: 8 Jul 2016

Go to URL

Last Updated: 5 Feb 2016

Go to URL

Last Updated: 30 May 2016

Go to URL